The second classification was proposed by the Consensus Molecular Subtypes (CMS) Consortium [9] which, by analyzing CRC expression profiling data from multiple studies, described four CMS groups associated with different patients’ outcomes: the first category CMS1 (MSI-immune, 14%) included CRC hypermutated due to dMMR with MSI and MLH1 silencing and accordingly CpG island hypermethylation phenotype-high (CIMP-high) with frequent BRAF mutations, and a low number of somatic copy number alterations (SCNAs). This evidence concerns the gene BRAF and colorectal carcinoma.